Nicolas  Fischer

Dr. Nicolas Fischer


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2010 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
URU. Ravn
U. Ravn
FGF. Gueneau
F. Gueneau
LBL. Baerlocher
L. Baerlocher
MOM. Osteras
M. Osteras
MDM. Desmurs
M. Desmurs
NFNicolas Fischer
Nicolas Fischer
In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, >1.9 × 10 7 sequences have been generated. This approach allowed for in depth analysis of the library’s diversity, provided sequence information on virtually all scFv during selection for binding to two targets and a global view of these enrichment processes. Using the most frequent heavy chain CDR3 sequences, primers were designed to rescue scFv from the third selection round. Identification, based on sequence frequency, retrieved the most potent scFv and valuable candidates that were missed using classical in vitro screening. Thus, by combining NGS with display technologies, laborious and time consuming upfront screening can be by-passed or complemented and valuable insights into the selection process can be obtained to improve library design and understanding of antibody repertoires.

12 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
NFNicolas Fischer
Nicolas Fischer
GEGreg Elson
Greg Elson
GMGiovanni Magistrelli
Giovanni Magistrelli
EDElie Dheilly
Elie Dheilly
NFNicolas Fouque
Nicolas Fouque
MKMarie Kosco-Vilbois
Marie Kosco-Vilbois
Bispecific antibodies enable unique therapeutic approaches but it remains a challenge to produce them at the industrial scale, and the modifications introduced to achieve bispecificity often have an impact on stability and risk of immunogenicity. Here we describe a fully human bispecific IgG devoid of any modification, which can be produced at the industrial scale, using a platform process. This format, referred to as a κλ-body, is assembled by co-expressing one heavy chain and two different light chains, one κ and one λ. Using ten different targets, we demonstrate that light chains can play a dominant role in mediating specificity and high affinity. The κλ-bodies support multiple modes of action, and their stability and pharmacokinetic properties are indistinguishable from therapeutic antibodies. Thus, the κλ-body represents a unique, fully human format that exploits light-chain variable domains for antigen binding and light-chain constant domains for robust downstream processing, to realize the potential of bispecific antibodies.

1 January 2011 in mAbs
Verified
Journal Article
Closed access
NFNicolas Fischer
Nicolas Fischer
Genomic studies have been revolutionized by the use of next generation sequencing (NGS) that delivers huge amounts of sequence information in a short span of time. The number of applications for NGS is rapidly expanding and significantly transforming many areas of life sciences. The field of antibody research and discovery is no exception. Several recent studies have harnessed the power of NGS for analyzing natural or synthetic immunoglobulin repertoires with unprecedented resolution and exploring alternative paths for antibody discovery. Thus, appreciating, and then exploiting, these advances is essential for staying at the edge of antibody innovation.

1 May 2007 in Pathobiology
Verified
Journal Article
Closed access
NFNicolas Fischer
Nicolas Fischer
OLOlivier Léger
Olivier Léger
Bispecific antibodies are unique in the sense that they can bind simultaneously two different antigens. This property enables the development of therapeutic strategies that are not possible with conventional monoclonal antibodies. The large panel of imaginative bispecific antibody formats that has been developed reflects the strong interest for these molecules. Although in many cases the manufacturing of clinical grade material remains challenging, several bispecific antibody formats are currently in clinical trials.

21 January 2015 in mAbs
Verified
Journal Article
Open access
PBPauline Bonvin
Pauline Bonvin
SVSophie Venet
Sophie Venet
GFGaëlle Fontaine
Gaëlle Fontaine
URUlla Ravn
Ulla Ravn
FGFranck Gueneau
Franck Gueneau
NFNicolas Fischer
Nicolas Fischer
PH-dependent antibodies are engineered to release their target at a slightly acidic pH, a property making them suitable for clinical as well as biotechnological applications. Such antibodies were previously obtained by histidine scanning of pre-existing antibodies, a labor-intensive strategy resulting in antibodies that displayed residual binding to their target at pH 6.0. We report here the de novo isolation of pH-dependent antibodies selected by phage display from libraries enriched in histidines. Strongly pH-dependent clones with various affinity profiles against CXCL10 were isolated by this method. Our best candidate has nanomolar affinity for CXCL10 at pH 7.2, but no residual binding was detected at pH 6.0. We therefore propose that this new process is an efficient strategy to generate pH-dependent antibodies.

21 December 2016 in mAbs
Verified
Journal Article
Open access
GMGiovanni Magistrelli
Giovanni Magistrelli
YPYves Poitevin
Yves Poitevin
FSFlorence Schlosser
Florence Schlosser
GPGuillemette Pontini
Guillemette Pontini
PMPauline Malinge
Pauline Malinge
NFNicolas Fischer
Nicolas Fischer
When production of bispecific antibodies requires the co-expression and assembly of three or four polypeptide chains, low expression of one chain can significantly limit assembly and yield. κλ bodies, fully human bispecific antibodies with native IgG structure, are composed of a common heavy chain and two different light chains, one kappa and one lambda. No engineering is applied to force pairing of the chains, thus both monospecific and bispecific antibodies are secreted in the supernatant. In this context, stoichiometric expression of the two light chains allows for maximal assembly of the bispecific antibody. In this study, we selected a κλ body with suboptimal characteristics due to low kappa chain expression. Codon optimization to increase expression of the kappa chain did not improve bispecific yield. Surprisingly, progressive introduction of non-optimal codons into the sequence of the lambda chain resulted in lowering its expression for an optimal tuning of the relative distribution of monospecific and bispecific antibodies. This codon de-optimization led to doubling of the κλ body yield. These results indicate that assembly of different proteins into a recombinant complex is an interconnected process and that reducing the expression of one polypeptide can actually increase the overall yield.